These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 4745832)
21. Narcotic antagonists in the treatment of opiate dependence. Fink M; Zaks A; Resnick RB; Freedman AM Int Z Klin Pharmakol Ther Toxikol; 1971 Jun; 4(4):455-8. PubMed ID: 5566728 [No Abstract] [Full Text] [Related]
22. Insoluble salts and salt complexes of cyclazocine and naloxone. Gray AP; Robinson DS Adv Biochem Psychopharmacol; 1973; 8(0):555-68. PubMed ID: 4800171 [No Abstract] [Full Text] [Related]
23. Effects of narcotic antagonists on fluid intake in the rat. Holtzman SG Life Sci; 1975 May; 16(9):1465-70. PubMed ID: 1134204 [No Abstract] [Full Text] [Related]
24. XXIX. The basis and possible utility of the use of opioid antagonists in the ambulatory treatment of the addict. Martin WR Res Publ Assoc Res Nerv Ment Dis; 1968; 46():367-77. PubMed ID: 5723804 [No Abstract] [Full Text] [Related]
25. The development of sustained action preparations of narcotic antagonists. Willette RE NIDA Res Monogr; 1976 Sep; (9):31-4. PubMed ID: 1004531 [No Abstract] [Full Text] [Related]
27. Historical perspective on the chemistry and development of naltrexone. Archer S NIDA Res Monogr; 1981; 28():3-10. PubMed ID: 6791011 [TBL] [Abstract][Full Text] [Related]
28. Use of narcotic (opiate) antagonists. Calesnick B Am Fam Physician; 1976 Mar; 13(3):158-9. PubMed ID: 1258715 [No Abstract] [Full Text] [Related]
29. Narcotic antagonists in opiate dependence. Fink M Science; 1970 Sep; 169(3949):1005-6. PubMed ID: 4914724 [No Abstract] [Full Text] [Related]
30. Comparison of the effects of cyclazocine and imipramine on the circadian sleep-waking cycle of the cat. Drew WG; Chamblin M; Miller LL Pharmacology; 1971; 6(6):339-52. PubMed ID: 4338399 [No Abstract] [Full Text] [Related]
31. Intravenous diacetylmorphine (heroin) in studies of opiate dependence. Zaks AM; Bruner A; Fink M; Freedman AM Dis Nerv Syst; 1969 Feb; 30(2):Suppl:89-92. PubMed ID: 4886996 [No Abstract] [Full Text] [Related]
32. Poly(hydroxy acids) in drug delivery. Juni K; Nakano M Crit Rev Ther Drug Carrier Syst; 1987; 3(3):209-32. PubMed ID: 3549007 [TBL] [Abstract][Full Text] [Related]
33. EVZIO: A New Delivery System for Naloxone. Lorman WJ J Addict Nurs; 2015; 26(4):217-8. PubMed ID: 26669230 [No Abstract] [Full Text] [Related]
34. INHIBITION OF PHENYLQUINONE-INDUCED WRITHING BY NARCOTIC ANTAGONISTS. TABER RI; GREENHOUSE DD; IRWIN S Nature; 1964 Oct; 204():189-90. PubMed ID: 14222271 [No Abstract] [Full Text] [Related]
35. Limitations on the antagonistic actions of opioid antagonists. Young AM; Woods JH Fed Proc; 1982 May; 41(7):2333-8. PubMed ID: 7042396 [TBL] [Abstract][Full Text] [Related]
36. Use of synthetic polypeptides in the preparation of biodegradable delivery systems for narcotic antagonists. Sidman KR; Schwope AD; Steber WD; Rudolph SE NIDA Res Monogr; 1981; 28():214-31. PubMed ID: 6791006 [TBL] [Abstract][Full Text] [Related]
37. Narcotic antagonists: the search for long-acting preparations: introduction. Willette RE Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):1-5. PubMed ID: 827708 [No Abstract] [Full Text] [Related]
38. Toxic interactions of stimulants, narcotics and narcotic antagonists. Leander JD; Lucot JB Res Commun Chem Pathol Pharmacol; 1977 Jun; 17(2):255-64. PubMed ID: 877411 [TBL] [Abstract][Full Text] [Related]
39. Certain theoretical and practical considerations involved in evaluating the overall abuse potential of opiate agonists and antagonists. Fraser HF Adv Biochem Psychopharmacol; 1973; 8(0):439-53. PubMed ID: 4604198 [No Abstract] [Full Text] [Related]